Total cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trail
Background The Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) double blind randomized trial demonstrated that weekly subcutaneous dulaglutide 1.5 mg, a glucagon like peptide-1 receptor agonist, versus matched placebo reduced the first outcome of major adverse cardiova...
Saved in:
Institution: | Universidad EIA |
---|---|
Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , |
Format: | Artículo de revista |
Language: | English |
Published: |
Cardiovascular Diabetology
2020-11-01
|
Online Access: | https://repositorio.udes.edu.co/handle/001/6024 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|